Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Hyperphosphatemia Contributes to Inflammation and Iron Dysregulation in Models of Normal and Impaired Renal Function

Brian Czaya, BS, MSc, Beatrice Richter, PhD, Christopher Yanucil, Bsc, Isaac Campos, Bsc, Kylie Heitman, Bsc, Christian Faul, PhD

Blood (2019) 134 (Supplement_1): 2238.

https://doi.org/10.1182/blood-2019-122144

Published: 2019

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Monica Kasbekar, Valentina Nardi, MD, Paola Dal Cin, Andrew M. Brunner, MD, Yi-Bin Chen, Christine Connolly, Amir T. Fathi, MD, Julia Foster, ANP, Molly Macrae, Steven L McAfee, MD, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, RN, Megan Vartanian, RN, Robb S Friedman, MD, Karim Benhadji, MD MSC, Gabriela S. Hobbs, MD

Blood (2019) 134 (Supplement_1): 5371.

https://doi.org/10.1182/blood-2019-124100

Published: 2019

Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 690.

https://doi.org/10.1182/blood-2018-99-110388

Published: 2018

Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Blood (2015) 126 (23): 496.

https://doi.org/10.1182/blood.V126.23.496.496

Published: 2015

Journal Articles

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Jeffrey Jones, MD, Anthony R. Mato, MD, Steven Coutre, MD, William Wierda, MD PhD, Michael Y. Choi, MD, Matthew S. Davids, MD, Nicole Lamanna, MD, Paul Barr, MD, Kim Burns, BA, Nicholas Montalvo, MBA, Ming Zhu, PhD, Todd Busman, MS, Jalaja Potluri, MD FACP, Rod A. Humerickhouse, MD PhD, John C. Byrd, MD

Blood (2015) 126 (23): 715.

https://doi.org/10.1182/blood.V126.23.715.715

Published: 2015

Journal Articles

Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies

Devon M Greer, PharmD, Jairam Krishnamurthy, MD, Susanne Liewer, PharmD, Mojtaba Akhtari, MD, Lori J. Maness, MD, R. Gregory Bociek, MD

Blood (2014) 124 (21): 2621.

https://doi.org/10.1182/blood.V124.21.2621.2621

Published: 2014

Journal Articles

Incidence of Treatment-Related, Laboratory and Clinical Tumor Lysis Syndrome

Mitchell S. Cairo, MD, Stephen Thompson, Lee Stern, Steven Sherman, MS

Blood (2012) 120 (21): 238.

https://doi.org/10.1182/blood.V120.21.238.238

Published: 2012

Journal Articles

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Sunil Sharma, MD, Emile Voest, MD, PhD, Nicole Hagner, MD, P.O. Witteveen, MD, PhD, Martijn Lolkema, MD, PhD, Neeraj Agarwal, MD, Sue-zette Valera, Jason Li, PhD, Derek Mires, Maria Grazia Porro, PhD, Margaret M. Woo, PharmD, Dagmar Hess, MD

Blood (2011) 118 (21): 5001.

https://doi.org/10.1182/blood.V118.21.5001.5001

Published: 2011

Journal Articles

Evaluation of Low Dose Rasburicase In the Prevention of Renal Insufficiency and Dialysis After Chemotherapy

Aflonso Eirin, MD, Maria V Irazabal, MD, Heidi D Gunderson, Nelson Leung, MD

Blood (2010) 116 (21): 2574.

https://doi.org/10.1182/blood.V116.21.2574.2574

Published: 2010

Journal Articles

High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Lillian Sung, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Richard Aplenc, MD, MSCE, Soheil Meshinchi, MD, PhD, Laura Burden, CCRP, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, BA, CCRP, Patti Byron, MSN, RN, Tanya Wallas, MS, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 1072.

https://doi.org/10.1182/blood.V116.21.1072.1072

Published: 2010

Journal Articles

Development of Renal Calculi and Imatinib Therapy in CML: Is There an Association?.

Tapan Saikia, MD, Nandini Hazarika, MD, Boman Dhabhar, MD

Blood (2007) 110 (11): 4551.

https://doi.org/10.1182/blood.V110.11.4551.4551

Published: 2007

Journal Articles

The Utilization of the Rand Appropriateness Method (RAM) and International Expert Opinion in the Development of Risk Stratification and Decision Model for Prophylaxis and Treatment of Tumor Lysis Syndrome (TLS).

Mitchell S. Cairo, MD, James P. Kahan, PhD, Marleen Cornelis, PhD, Bertrand Coiffier, MD

Blood (2006) 108 (11): 3316.

https://doi.org/10.1182/blood.V108.11.3316.3316

Published: 2006

Journal Articles

Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

David M. Lucas, PhD, Syed-Rehan A. Hussain, PhD, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Jamie M. Allison, BA, Sara E. Guster, MS/MBA, Thomas S. Lin, MD, John C. Byrd, MD, Mark W. Julian, PhD, Elliott D. Crouser, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2098.

https://doi.org/10.1182/blood.V108.11.2098.2098

Published: 2006

Journal Articles

SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.

Yves Bertrand, Anne Auvrignon, MD, Brigitte Nelken, MD, Valérie Mialoux, MD, Francoise Mechinaud, MD, Catherine Patte, MD, Dominique Plantaz, MD, Nathalie Le Guyader, MD, Marisol Urbieta, MD, Yves Perel, Andre Baruchel9, Guy Leverger

Blood (2005) 106 (11): 3122.

https://doi.org/10.1182/blood.V106.11.3122.3122

Published: 2005

Journal Articles

Recommandations of the Societe Francaise des Cancers de l’Enfant (SFCE) for the Management of Tumors Lysis Syndrom (TLS) : A Validation Survey.

Y. Bertrand, A. Auvrignon, B. Nelken, V. Mialou, F. Mechinaud, B. Brethon, C. Patte, D. Plantaz, M. Urbieta, A. Baruchel, G. Leverger

Blood (2004) 104 (11): 5295.

https://doi.org/10.1182/blood.V104.11.5295.5295

Published: 2004

Journal Articles

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Anthony R. Mato, MD, Brett E. Riccio, MD, Li Qin, PhD, Daniel Heitjan, PhD, Alison Loren, MD, Martin Carroll, MD, David Porter, MD, Donald Tsai, MD, Edward Stadtmauer, MD, Sasha Perl, MD, Alan Gewirtz, MD, Sunita Nasta, MD, Stephen Schuster, MD, Steven Goldstein, MD, Selina M. Luger, MD

Blood (2004) 104 (11): 883.

https://doi.org/10.1182/blood.V104.11.883.883

Published: 2004

NARROW

Hyperphosphatemia Contributes to Inflammation and Iron Dysregulation in Models of Normal and Impaired Renal Function

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies

Incidence of Treatment-Related, Laboratory and Clinical Tumor Lysis Syndrome

Effects of Renal Function on the Pharmacokinetics of Panobinostat in Patients with Advanced Cancer: A Phase I Study

Evaluation of Low Dose Rasburicase In the Prevention of Renal Insufficiency and Dialysis After Chemotherapy

High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Development of Renal Calculi and Imatinib Therapy in CML: Is There an Association?.

The Utilization of the Rand Appropriateness Method (RAM) and International Expert Opinion in the Development of Risk Stratification and Decision Model for Prophylaxis and Treatment of Tumor Lysis Syndrome (TLS).

Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.

Recommandations of the Societe Francaise des Cancers de l’Enfant (SFCE) for the Management of Tumors Lysis Syndrom (TLS) : A Validation Survey.

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only